Very few peptide compounds have received FDA approval so far. However, peptides and proteins compose over 60% of pharmaceutical pipelines under development. As research continues, more peptide drugs will likely reach approval status. Many peptide therapies remain accessible currently through specialized clinics and compounding pharmacies.